Dana-Farber's David Weinstock, MD, and colleagues report that a novel compound stops B-cell acute lymphoblastic leukemia tumor cell growth in pre-clinical studies; approach may be effective in other cancers as well.

Dana-Farber's Molecular Cancer Imaging Facility in Boston's Innovation District will use cutting edge technology for research on improving cancer diagnosis and developing precision drugs matched to individual patients.

A new technology developed at Dana-Farber may make it possible to target "undruggable" proteins and overcome drug resistance by using a cancer cell's own protein-degrading machinery to destroy, not just inhibit, cancer proteins.

Dana-Farber/Brigham and Women's Cancer Center has a new website to connect patients and physicians with information about precision cancer medicine, including resources on what precision cancer is and how it can be applied to cancer care today.

Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health in Boston and the Irish Cancer Society have formed the Boston-Ireland Prostate Cancer Collaboration. This new entity will conduct and facilitate exchanges of researchers and knowledge between Boston and Ireland.